Assertio Holdings, Inc. (ASRT) has a MoatMap StockRank of 74/100 based on Quality (35/100), Value (39/100), and Momentum (84/100) factor scores. The current signal is BUY. Assertio Holdings is a specialty pharmaceutical company with a history of acquisitions. It lacks a proprietary manufacturing moat or CDMO pricing power, operating a fragile business model reliant on legacy commercialized drugs.
Assertio Holdings, Inc. is a commercial-stage pharmaceutical company focused on acquiring, developing, and commercializing branded and authorized generic therapeutics across neurology, pain, and inflammation. The company differentiates itself by leveraging a lean operating model and established commercial infrastructure to maximize the value of its product portfolio. Assertio targets niche markets with recognized medical needs.
| Price | $23.46 |
| Market Cap | $151M |
| P/E (Forward) | 9.09 |
| Price/Book | 2.00 |
| Return on Equity | -38.8% |
| Return on Invested Capital | -19.6% |
| Debt/Equity | 53.30 |
| Gross Margin | 70.3% |
| Operating Margin | -185.9% |
| Revenue Growth | -62.5% |
| Free Cash Flow | $8M |
Assertio Holdings, Inc. operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector (United States).